Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia

Published:September 22, 2017DOI:https://doi.org/10.1016/j.jacl.2017.09.003

      Highlights

      • Long-term evolocumab was evaluated in heterozygous familial hypercholesterolemia.
      • Evolocumab plus standard of care led to a mean 53.6% low-density lipoprotein cholesterol reduction at 48 weeks.
      • Serious adverse event rates did not increase with evolocumab vs standard of care.

      Background

      Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in patients with heterozygous familial hypercholesterolemia (HeFH) as demonstrated in two 12-week trials: Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD; phase 2) and RUTHERFORD-2 (phase 3).

      Objective

      The objective of the study was to evaluate long-term efficacy, safety, and tolerability of evolocumab during open-label extension trials.

      Methods

      Patients completing parent trials were re-randomized 2:1 to evolocumab plus standard of care (SOC) or SOC alone for 52 weeks (Open-Label Study of Long-term Evaluation Against LDL-C [OSLER-1]) or 48 weeks (OSLER-2). Evolocumab dosing was 420 mg QM (OSLER-1) and 140 mg Q2W or 420 mg QM (OSLER-2). A pooled analysis of OSLER data was performed from this subset of HeFH patients.

      Results

      Four hundred forty HeFH patients from RUTHERFORD (n = 147) and RUTHERFORD-2 (n = 293) (mean [standard deviation] age 51 [12] years, 58% male, 90% White) were randomized to evolocumab plus SOC (n = 289) or SOC (n = 151). The 48-week period was completed by 425 patients (96.6%). Eight patients discontinued evolocumab plus SOC (2.8%) and 7 discontinued SOC (4.6%). Compared to parent study baseline, patients receiving evolocumab plus SOC experienced a mean 53.6% reduction in low-density lipoprotein cholesterol after 48 weeks. No patient experienced an adverse event leading to permanent evolocumab discontinuation during the 1-year SOC-controlled period. Serious adverse event rates were similar between groups (evolocumab plus SOC, 7.3%; SOC, 8.6%).

      Conclusion

      Continued use of evolocumab added to SOC in patients with HeFH yields persistent and marked low-density lipoprotein cholesterol reductions during 48 weeks of follow-up. Long-term dosing of evolocumab with SOC was safe and well tolerated.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leigh S.E.
        • Foster A.H.
        • Whittall R.A.
        • Hubbart C.S.
        • Humphries S.E.
        Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database.
        Ann Hum Genet. 2008; 72: 485-498
        • Abifadel M.
        • Varret M.
        • Rabes J.P.
        • et al.
        Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
        Nat Genet. 2003; 34: 154-156
        • Cenarro A.
        • Etxebarria A.
        • de Castro-Oros I.
        • et al.
        The p.Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes.
        J Clin Endocrinol Metab. 2016; 101: 2113-2121
        • Fouchier S.W.
        • Dallinga-Thie G.M.
        • Meijers J.C.
        • et al.
        Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.
        Circ Res. 2014; 115: 552-555
        • Soria L.F.
        • Ludwig E.H.
        • Clarke H.R.
        • Vega G.L.
        • Grundy S.M.
        • McCarthy B.J.
        Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.
        Proc Natl Acad Sci U S A. 1989; 86: 587-591
        • de Ferranti S.D.
        • Rodday A.M.
        • Mendelson M.M.
        • Wong J.B.
        • Leslie L.K.
        • Sheldrick R.C.
        Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES).
        Circulation. 2016; 133: 1067-1072
        • Nordestgaard B.G.
        • Chapman M.J.
        • Humphries S.E.
        • et al.
        Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.
        Eur Heart J. 2013; 34: 3478-3490a
        • Neil A.
        • Cooper J.
        • Betteridge J.
        • et al.
        Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
        Eur Heart J. 2008; 29: 2625-2633
        • Pijlman A.H.
        • Huijgen R.
        • Verhagen S.N.
        • et al.
        Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.
        Atherosclerosis. 2010; 209: 189-194
        • Stein E.A.
        • Ose L.
        • Retterstol K.
        • et al.
        Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia.
        J Clin Lipidol. 2007; 1: 280-286
        • Versmissen J.
        • Oosterveer D.M.
        • Yazdanpanah M.
        • et al.
        Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
        BMJ. 2008; 337: a2423
        • Khera A.V.
        • Won H.H.
        • Peloso G.M.
        • et al.
        Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
        J Am Coll Cardiol. 2016; 67: 2578-2589
        • Benn M.
        • Watts G.F.
        • Tybjaerg-Hansen A.
        • Nordestgaard B.G.
        Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
        J Clin Endocrinol Metab. 2012; 97: 3956-3964
        • Mundal L.
        • Sarancic M.
        • Ose L.
        • et al.
        Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010.
        J Am Heart Assoc. 2014; 3: e001236
        • Perak A.M.
        • Ning H.
        • de Ferranti S.D.
        • Gooding H.C.
        • Wilkins J.T.
        • Lloyd-Jones D.M.
        Long-term risk of atherosclerotic cardiovascular disease in US adults with the familial hypercholesterolemia phenotype.
        Circulation. 2016; 134: 9-19
        • Perez de Isla L.
        • Alonso R.
        • Mata N.
        • et al.
        Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART registry (Spanish Familial Hypercholesterolaemia Cohort Study).
        Arterioscler Thromb Vasc Biol. 2016; 36: 2004-2010
        • Raal F.
        • Scott R.
        • Somaratne R.
        • et al.
        Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial.
        Circulation. 2012; 126: 2408-2417
        • Raal F.J.
        • Stein E.A.
        • Dufour R.
        • et al.
        PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2015; 385: 331-340
      1. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.
        BMJ. 1991; 303: 893-896
        • Sjouke B.
        • Kusters D.M.
        • Kindt I.
        • et al.
        Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
        Eur Heart J. 2015; 36: 560-565
        • Tai E.S.
        • Koay E.S.
        • Chan E.
        • et al.
        Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia.
        Clin Chem. 2001; 47: 438-443
        • Usifo E.
        • Leigh S.E.
        • Whittall R.A.
        • et al.
        Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment.
        Ann Hum Genet. 2012; 76: 387-401
        • Myers G.L.
        • Cooper G.R.
        • Winn C.L.
        • Smith S.J.
        The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements.
        Clin Lab Med. 1989; 9: 105-135
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Beyer-Westendorf J.
        • Buller H.
        External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? Journal of thrombosis and haemostasis.
        J Thromb Haemost. 2011; 9: 2153-2158
        • Rojas-Fernandez C.H.
        • Goldstein L.B.
        • Levey A.I.
        • Taylor B.A.
        • Bittner V.
        • The National Lipid Association's Safety Task Force
        An assessment by the Statin Cognitive Safety Task Force: 2014 update.
        J Clin Lipidol. 2014; 8: S5-S16
        • Sattar N.
        • Preiss D.
        • Murray H.M.
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Strom B.L.
        • Schinnar R.
        • Karlawish J.
        • Hennessy S.
        • Teal V.
        • Bilker W.B.
        Statin therapy and risk of acute memory impairment.
        JAMA Intern Med. 2015; 175: 1399-1405
        • Ference B.A.
        • Robinson J.G.
        • Brook R.D.
        • et al.
        Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes.
        N Engl J Med. 2016; 375: 2144-2153
        • Sabatine M.S.
        • Giugliano R.P.
        • Keech A.C.
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Giugliano R.P.
        • Mach F.
        • Zavitz K.
        • et al.
        Cognitive function in a randomized trial of evolocumab.
        N Engl J Med. 2017; 377: 633-643
        • Toth P.P.
        • Descamps O.
        • Genest J.
        • et al.
        Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies.
        Circulation. 2017; 135: 1819-1831
        • Braamskamp M.J.
        • Kusters D.M.
        • Avis H.J.
        • et al.
        Long-term statin treatment in children with familial hypercholesterolemia: more insight into tolerability and adherence.
        Paediatr Drugs. 2015; 17: 159-166
        • van der Graaf A.
        • Cuffie-Jackson C.
        • Vissers M.N.
        • et al.
        Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
        J Am Coll Cardiol. 2008; 52: 1421-1429
        • Talmud P.J.
        • Shah S.
        • Whittall R.
        • et al.
        Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
        Lancet. 2013; 381: 1293-1301
        • Besseling J.
        • Kindt I.
        • Hof M.
        • Kastelein J.J.
        • Hutten B.A.
        • Hovingh G.K.
        Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
        Atherosclerosis. 2014; 233: 219-223